2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Imaging, Treatment Considerations, Therapy Sequence, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries
PAPER

517 Ten-year follow-up of a PET-guided approach for limited-stage DLBCL demonstrates differential outcomes based on IPI and cell-of-origin

Odil Giladi, MD, David Scott, MD2, Aixiang Jiang, PhD3, Diego Villa, MD4, Alina S. Gerrie, MD, FRCPC, MPH5, Christopher P. Venner, MD6, Andrew J. Cowan, MD7, Barbara Meissner8, Andrea C. Lo, MD, MPH9, Pedro Farinha, MD, PhD10, Andrew Lytle, MD, PhD11, Graham Slack12, Don Wilson13, Kerry Savage, MD, MSc, BSc14, Laurie H. Sehn, MD15
1 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
2 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
3 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada
4 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
5 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
6 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
7 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
8 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada
9 Division of Radiation Oncology, Vancouver, British Columbia, Canada
10 Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
11 Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
12 Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
13 Department of Functional Imaging, Vancouver, British Columbia, Canada
14 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada
15 BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada, Division of Medical Oncology, Vancouver, British Columbia, Canada

Background: Treatment guidelines for limited-stage diffuse large B-cell lymphoma (DLBCL) endorse abbreviated therapy, with PET-guided strategies commonly used. However, long-term outcome data are limited, and little is known about the impact of cell-of-origin (COO) in this setting. We present 10-year outcome of patients (pts) with limited-stage DLBCL (stage I/II, no B-symptoms, mass <10 cm, radiation encompassable) uniformly treated according to a PET-based management algorithm in British Columbia (BC). This algorithm recommends interim PET/CT after 3 cycles of R-CHOP: PET-positive (pos) pts (defined as uptake >mediastinal blood pool; by IHP prior to 2013, then Deauville score 3-5 subsequently) receive involved-site radiation therapy (RT); PET-negative (neg) pts receive one additional cycle of R-CHOP.     

Methods: Using the BC Cancer Centre for Lymphoid Cancer Database, we identified all pts diagnosed with limited-stage DLBCL between Mar 2005 and Apr 2026 intended for this PET-guided treatment approach. Pts with primary CNS, primary testicular, PMBCL, PTLD, and transformed or discordant/composite lymphoma were excluded. COO was determined by digital gene expression profiling (GEP) when available; otherwise, the Hans IHC algorithm was used. Time-to-progression (TTP) was calculated from diagnosis to date of progression or death from lymphoma or treatment toxicity; deaths due to unrelated causes were censored.

Results: 505 pts were identified: median age 69 y (range 19–92); 52% male; 60% stage I; 40% stage II; 8% ECOG PS ≥2; 12% elevated LDH; 47% with at least one extranodal site; and 38% with mass size ≥5 cm. Stage-modified (sm) IPI risk score: 17%, 0; 44%, 1; 39%, 2-4. COO was available for 402/505 (80%) pts, with 202 (50%) by GEP: 248 (62%) GCB; 131 (33%) ABC/non-GCB; 23 (6%) unclassified. With median follow-up of 10.2 y (range 0.16–20.9), 5-y and 10-y TTP of the entire cohort were 86.7% and 80.0%, 5-y and 10-y PFS were 79.6% and 63.8%, and 5-y and 10-y OS were 82.9% and 67.5%, respectively. Twelve pts (2%) did not undergo interim PET primarily due to treatment intolerance and 6 pts (1%) had an indeterminate PET. Of the 487 evaluable pts that underwent interim PET after 3 cycles of R-CHOP, 388 (80%) pts were PET-neg and 99 (20%) pts were PET-pos. 90% of PET-neg pts were treated per protocol with 4 cycles of R-CHOP, 4.4% received RT. 84% of PET-pos pts received RT per protocol, while 10% with Deauville score 3 received 4 cycles of R-CHOP per physician choice. In total, 54/388 (13.9%) PET-neg pts and 21/99 (21%) PET-pos pts relapsed/progressed. TTP was higher in PET-neg pts (5-y and 10-y TTP 90.0% and 82.9%) compared with PET-pos pts (5-y and 10-y TTP 79.7% and 73.6%), p=0.02. Patients with low risk smIPI (0 or 1) had a favorable outcome (5-y and 10-y TTP 93.6% and 87.2%) compared with high risk smIPI (2-4) (5-y and 10-y TTP 75.4% and 69.0%), p<0.0001. Outcomes were notably better in GCB pts (5-y and 10-y TTP 92.3% and 84.1%) compared with ABC/non-GCB pts (5-y and 10-y TTP 80.9% and 74.5%), p=0.01. ABC/non-GCB pts with an IPI score of 2 or higher (who would have been eligible for the POLARIX trial), had especially poor outcomes (5-y and 10-y TTP of 59.8% and 59.8%). On univariate analysis, age, ECOG PS, stage, smIPI, and COO (by GEP and/or IHC) were significant predictors of TTP. On multivariate analysis, both smIPI (p=0.003) and COO (p=0.035) remained independent predictors of TTP. Late relapses (>5y) were frequent, making up 35% and 14% of relapses in PET-neg and PET-pos pts, respectively. Occurring in both GCB and ABC pts, they were more common in GCB pts (40% vs 19% of relapses). Of note, 2/22 (9%) late relapses were follicular lymphoma (FL) alone, with 1 additional pt having both FL and DLBCL (all in GCB pts).

Conclusions: This retrospective analysis represents the largest reported population-based cohort of pts with limited-stage DLBCL uniformly treated with PET-guided abbreviated therapy. While overall outcomes are favorable, alternative approaches may be appropriate for higher risk patients based on smIPI and COO, and for pts who remain PET-pos after 3 cycles. The propensity for late relapse is striking and warrants further exploration of the unique biology within this subgroup of patients. The pattern of relapse raises the possibility of a persistent precursor cell that is not fully eradicated with an abbreviated approach.

Odil Giladi, MD: No relevant conflicts of interest to declare.